Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate

Journal of Clinical Oncology

Volumn 22, Issue 10, 2004, Pages 1909-1915

  Kumar, Parvesh ^a   Perrotti, Michael ^a   Weiss, Robert ^a   Todd, Mary ^a   Goodin, Susan ^a   Cummings, Kenneth ^a   DiPaola, Robert S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; TAXOID;

ARTICLE; CATHETERIZATION; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG TOLERANCE; DYSURIA; HUMAN; MALE; MAXIMUM PERMISSIBLE DOSE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; REMISSION; TOXICITY; ADENOCARCINOMA; AGED; CANCER STAGING; COMPUTER ASSISTED RADIOTHERAPY; DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PROSTATE TUMOR; RADIATION DOSE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIOTHERAPY, CONFORMAL; TAXOIDS; TREATMENT OUTCOME;

EID: 3042781698     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.02.001     Document Type: Article

References (29)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54:8-29, 2004
2. Hanks GE, Hanlon AL, Epstein B, et al: Dose response in prostate cancer with 8-12 years follow-up. Int J Radiat Oncol Biol Phys 54:427-435, 2002
3. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997
4. Pilepich MV, Winter K, John MJ, et al: Phase Il Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50:1243-1252, 2001
5. Pilpepich MV, Winter K, Lawton C, et al: Phase III trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31. Proc Am Soc Clin Oncol 22:381, 2003 (abstr 1530)
6. Hanks GE, Pajak TF, Porter A, et al: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21:3972-3978, 2003
7. Bolla M, Gonzales D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997
8. Gastrointestinal Tumor Study Group. Survival after postoperative combination treatment of rectal cancer. N Engl J Med 315:1294-1295, 1986
9. Tveit KM, Guldvog I, Hagen S, et al: Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes' B and C rectal cancer. Br J Surg 84:1130-1135, 1997
10. Nigro ND: Multimodisciplinary management of cancer of the anus. World J Surg 11: 446-451, 1987
11. Diaz JF, Andreu JM: Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: Reversibility, ligand stoichiometry, and competition. Biochemistry 32:2747-2755, 1993
12. Ringel I, Horwitz SB: Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83:288-291, 1991
13. Hennequin C, Giocanti N, Favaudon V: Interaction of Ionizing Radiation with Paclitaxel (Taxol) and Docetaxel (Taxotere) in HeLa and SQ20B Cells. Cancer Res 56:1842-1850, 1996
14. Milas L, Milas MM, Mason KA: Combination of taxanes with radiation: Preclinical studies. Semin Radiat Oncol 9:12-26, 1999
15. Mason KA, Hunter NR, Milas M, et al: Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 3:2431-2438, 1997
16. Picus J, Shultz M: Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory cancer: Preliminary results. Semin Oncol 29:14-18, 1999(suppl 17)
17. Friedland D, Cohen J, Miller R, et al: A phase II trial of docetaxel in hormone-refractory prostate cancer: Correlation of antitumor effect to phosphorylation of bcl-2. Semin Oncol 26:19-23, 1999 (5 suppl 7)
18. Kreis W, Budman DR, Fetten J, et al: Phase I trial of the combination of daily estra-mustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 10:33-38, 1999
19. Petrylak DP, Macarthur RB, O'Connor J, et al: Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17:958-967, 1999
20. Savarese DM, Halabi S, Hars V, et al: Phase Il study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 19:2509-2516, 2001
21. Berry W, Dakhil S, Regich M, et al: Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28:8-15, 2001 (4 suppl 15)
22. Beer T, Pierce WC, Lowe BA, et al: Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12:1273-1279, 2001
23. DiPaola R, Kumar P, Hait W, et al: State-of-the-art prostate cancer treatment and research. A report from The Cancer Institute of New Jersey. N J Med 98:23-33, 2001
24. Roach M 3rd, Lu JD, Lawton C, et al: A Phase III Trial Comparing Whole-Pelvic (WP) to Prostate Only (PO) Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression (TAS): Preliminary Analysis of RTOG 9413. Int J Radiat Oncol Biol Phys 51:3, 2001 (abstr 5)
25. Zelefsky MJ, Kelly WK, Scher H, et al: Results of a Phase Il study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer. J Clin Oncol 18:1936-1941, 2000
26. Ben-Josef E, Porter AT, Han S, et al: Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: Feasibility and preliminary results. Int J Radiat Oncol Biol Phys 49:699-703, 2001
27. Khil MS, Kim JH, Bricker LJ, et al: Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy. Cancer J Sci Am 3:289-296, 1997
28. Koukourakis MI, Kourousis C, Kamilaki M, et al: Weekly docetaxel and concomitant boost radiotherapy for non-small-cell lung cancer. A phase I/II dose escalation trial. Eur J Cancer 34:838-844, 1998
29. Mauer AM, Masters GA, Haraf DH, et al: Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16:159-164, 1998